74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
TG Therapeutics Inc
Closed
Sector Healthcare
30.85 -0.32
Overview
Share price change
24h
Min
30.5
Max
30.85
Income | -3M 3.9M |
|---|---|
Sales | 10M 84M |
P/E Sector Avg | 59.3 73.394 |
EPS | 0.02 |
Profit margin | 4.626 |
Employees | 319 |
EBITDA | 4.5M 15M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +30.6 upside |
Next Earnings | 26 Feb 2025 |
|---|
Market Cap | -68M 4.8B |
|---|---|
Previous open | 31.17 |
Previous close | 30.85 |
News Sentiment
By Acuity
12%
88%
12 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
TG Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
TG Therapeutics Inc Forecast
Price Target
By TipRanks
30.6% upside
12 Months Forecast
Average 40.33 USD 30.6%
High 55 USD
Low 10 USD
Based on 6 Wall Street analysts offering 12 month price targets forTG Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
12 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About TG Therapeutics Inc
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).
